Who Paid My Doc
Muna Qayed
Pediatric Hematology-Oncology Atlanta, GA Medical Doctor
NPI 1508074568 CMS profile 204371
1405 Clifton Rd Ne, Atlanta, GA 30322
General payments
$85,733
Research payments
$1,734
Ownership & investment interest
$0
Research they led as principal investigator
$861,098
Through program year 2025, Muna Qayed of Atlanta, GA is reported in the CMS Open Payments database as having received $85,733 across 60 general payments and $1,734 in research payments paid to them. Separately, studies naming them as principal investigator received $861,098 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $18,678 | 15 | |
| 2025 | Research | $1,288 | 1 | |
| 2024 | General | $4,104 | 7 | |
| 2024 | Research | $446 | 1 | |
| 2023 | General | $29,430 | 16 | |
| 2022 | General | $22,270 | 10 | |
| 2021 | General | $6,721 | 4 | |
| 2020 | General | $49 | 1 | |
| 2019 | General | $4,481 | 7 |
Beside peers
- Muna Qayed
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Muna Qayed were reported at $18,678. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Muna Qayed | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,481 | $184 | $69–$2,094 | $163 |
| 2020 | $49 | $220 | $37–$3,941 | $114 |
| 2021 | $6,721 | $366 | $63–$4,909 | $132 |
| 2022 | $22,270 | $181 | $66–$2,775 | $149 |
| 2023 | $29,430 | $175 | $62–$2,600 | $160 |
| 2024 | $4,104 | $227 | $66–$2,992 | $164 |
| 2025 | $18,678 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
62 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Hematology-Oncology in Georgia
Robert Sidonio
Pediatric Hematology-Oncology · Atlanta, GA
Shannon Meeks
Pediatric Hematology-Oncology · Atlanta, GA
Bhavya Doshi
Pediatric Hematology-Oncology · Atlanta, GA
Cindy Neunert
Pediatric Hematology-Oncology · Augusta, GA
Shanmuganathan Chandrakasan
Pediatric Hematology-Oncology · Atlanta, GA
Betty Pace
Pediatric Hematology-Oncology · Augusta, GA
Related records
Pediatric Hematology-Oncology in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.